Flagship spins out $50M startup to mine new drugs from genetic mutations

Cambridge venture firm Flagship Pioneering's latest startup is starting very small: It's looking for mutations at the cellular level to find, then target, genetic causes of disease.

Previous New KeyBank exec says Q4 insight will tell where economy is headed
Next Southern Tier hospital plans $8.4M renovation